首页 > 最新文献

Gynecologic and Obstetric Investigation最新文献

英文 中文
Pain Level and Analgesic Requirements in Patients Who Underwent Vaginal Pelvic Floor Surgery following General or Spinal Anesthesia. 全身麻醉或脊髓麻醉后阴道盆底手术患者的疼痛水平和镇痛需求。
IF 2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-12-02 DOI: 10.1159/000541962
Zehava Yohay, Yair Binyamin, Alla Saban, Adi Y Weintraub, Nurit Cohen, Neriya Zion Yohay, Michael Dubilet

Objective: This retrospective cohort study aimed to investigate postoperative pain levels and analgesic drug requirements in women who underwent general anesthesia (GA) or spinal anesthesia (SA) during vaginal pelvic floor surgeries.

Design: This was a retrospective cohort study.

Participants/materials, setting, methods: Women aged 18 or above who underwent vaginal pelvic floor surgery between 2019 and 2021 were included in the study. Univariate and multivariate analyses were performed separately for vaginal wall repair and stress urinary incontinence surgery.

Results: During the study period, 101 women underwent surgery under SA, and 99 women underwent surgery under GA. Intravenous analgesia administration rates were significantly lower under SA for both vaginal wall repair (20.2% vs. 38.9%, p = 0.017) and mid-urethral sling placement (20.2% vs. 37.8%, p = 0.007). Multivariate analysis revealed that intravenous analgesia requirement was significantly lower in the SA group than in the GA group after controlling for patient's age, concurrent hysterectomy, and mesh placement for vaginal wall repair (aOR = 0.33, p = 0.008) and mid-urethral sling placement (aOR = 0.37, p = 0.004).

Limitations: This is a retrospective study, thus the choice of anesthesia may be biased.

Conclusion: SA is associated with less postoperative pain and intravenous analgesia requirement in women who undergo vaginal pelvic floor surgeries. However, further research is needed to determine the preferred anesthesia method for specific types of pelvic floor surgeries.

目的:本回顾性队列研究旨在调查阴道盆底手术中接受GA或SA的女性术后疼痛水平和镇痛药物需求。设计:回顾性队列研究。参与者/材料、环境、方法:在2019年至2021年期间接受阴道盆底手术的18岁或以上女性纳入研究。对阴道壁修复和压力性尿失禁手术分别进行单因素和多因素分析。结果:在研究期间,101例女性在SA下手术,99例女性在GA下手术。阴道壁修复(20.2% vs. 38.9%, P=0.017)和尿道中悬吊带放置(20.2% vs. 37.8%, P= 0.007)在SA下静脉镇痛给药率均显著低于阴道壁修复(20.2% vs. 38.9%, P=0.017)。多因素分析显示,在控制患者年龄、同时切除子宫、放置阴道壁补片(aOR= 0.33, p=0.008)和放置尿道中吊带(aOR= 0.37, p=0.004)后,SA组静脉镇痛需求显著低于GA组。局限性:这是一项回顾性研究,因此麻醉的选择可能有偏倚。结论:SA与接受阴道盆底手术的妇女术后疼痛和静脉镇痛需求减少有关。然而,需要进一步的研究来确定特定类型盆底手术的首选麻醉方法。关键词:全身麻醉;脊髓麻醉,镇痛,盆底手术,盆腔器官脱垂,压力性尿失禁,eras。摘要:脊柱麻醉下阴道盆底手术术后疼痛和静脉镇痛需求较少。
{"title":"Pain Level and Analgesic Requirements in Patients Who Underwent Vaginal Pelvic Floor Surgery following General or Spinal Anesthesia.","authors":"Zehava Yohay, Yair Binyamin, Alla Saban, Adi Y Weintraub, Nurit Cohen, Neriya Zion Yohay, Michael Dubilet","doi":"10.1159/000541962","DOIUrl":"10.1159/000541962","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective cohort study aimed to investigate postoperative pain levels and analgesic drug requirements in women who underwent general anesthesia (GA) or spinal anesthesia (SA) during vaginal pelvic floor surgeries.</p><p><strong>Design: </strong>This was a retrospective cohort study.</p><p><strong>Participants/materials, setting, methods: </strong>Women aged 18 or above who underwent vaginal pelvic floor surgery between 2019 and 2021 were included in the study. Univariate and multivariate analyses were performed separately for vaginal wall repair and stress urinary incontinence surgery.</p><p><strong>Results: </strong>During the study period, 101 women underwent surgery under SA, and 99 women underwent surgery under GA. Intravenous analgesia administration rates were significantly lower under SA for both vaginal wall repair (20.2% vs. 38.9%, p = 0.017) and mid-urethral sling placement (20.2% vs. 37.8%, p = 0.007). Multivariate analysis revealed that intravenous analgesia requirement was significantly lower in the SA group than in the GA group after controlling for patient's age, concurrent hysterectomy, and mesh placement for vaginal wall repair (aOR = 0.33, p = 0.008) and mid-urethral sling placement (aOR = 0.37, p = 0.004).</p><p><strong>Limitations: </strong>This is a retrospective study, thus the choice of anesthesia may be biased.</p><p><strong>Conclusion: </strong>SA is associated with less postoperative pain and intravenous analgesia requirement in women who undergo vaginal pelvic floor surgeries. However, further research is needed to determine the preferred anesthesia method for specific types of pelvic floor surgeries.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"1-7"},"PeriodicalIF":2.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Model for Predicting Severe Intra-Abdominal Adhesions following Prior Cesarean Sections. 预测剖宫产术后严重腹内粘连的模型。
IF 2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-28 DOI: 10.1159/000542825
Shai Ram, Hila Shalev-Ram, Shira Alon, Ziv Shapira, Roza Berkovitz-Shperling, Margaret Johansson-Lipinski, Yariv Yogev, Ariel Many

Objective: The increasing rate of cesarean sections (CSs) raises concerns over severe intra-abdominal adhesions, which are associated with numerous complications. We aimed to identify risk factors and predictive tools for severe adhesions.

Design: A prospective study was conducted. Participants/Materials: Women with at least one prior CS were evaluated.

Setting: The study was conducted at a tertiary medical center from January to July 2021.

Methods: Surgeons assessed adhesions at four anatomical sites, scoring them from 0 (none) to 2 (dense), with a total possible score of 0-8. Severe adhesions were defined as a score of ≥5. Risk factors were analyzed using logistic regression to create a prediction model.

Results: Overall, 341 women were included in the study. Significant predictors included the number of previous CS, maternal body mass index, maternal morbidity at the time of the previous CS, and operation time. The model predicted severe adhesions with 79.1% accuracy, a positive predictive value of 68.4%, and a negative predictive value of 79.5%.

Limitations: Few risk factors, such as surgical history beyond cesarean sections, endometriosis, and pelvic inflammatory disease were not available. Additionally, the sample size of 341 women, while substantial, may limit the identification of further risk factors and the precision of the predictive model.

Conclusion: The severity of most cases of post-CS adhesions can be predicted by a model which considers common risk factors.

目的:剖宫产率的上升引起了人们对严重腹内粘连的关注,这与许多并发症有关。我们的目的是确定严重粘连的危险因素和预测工具。方法:在2021年1月至7月在一家三级医疗中心进行的一项前瞻性研究中,对至少有一次CS病史的女性进行了评估。外科医生评估了4个解剖部位的粘连,从0(无)到2(致密)进行评分,总分为0-8。严重粘连的定义为评分≥5分。采用logistic回归分析危险因素,建立预测模型。结果:总共有341名女性参与了这项研究。有意义的预测因素包括既往CS次数、母体BMI、既往CS时母体发病率和手术时间。该模型预测严重粘连的准确率为79.1%,阳性预测值为68.4%,阴性预测值为79.5%。结论:考虑常见危险因素的模型可以预测大多数cs后粘连的严重程度。
{"title":"A Model for Predicting Severe Intra-Abdominal Adhesions following Prior Cesarean Sections.","authors":"Shai Ram, Hila Shalev-Ram, Shira Alon, Ziv Shapira, Roza Berkovitz-Shperling, Margaret Johansson-Lipinski, Yariv Yogev, Ariel Many","doi":"10.1159/000542825","DOIUrl":"10.1159/000542825","url":null,"abstract":"<p><strong>Objective: </strong>The increasing rate of cesarean sections (CSs) raises concerns over severe intra-abdominal adhesions, which are associated with numerous complications. We aimed to identify risk factors and predictive tools for severe adhesions.</p><p><strong>Design: </strong>A prospective study was conducted. Participants/Materials: Women with at least one prior CS were evaluated.</p><p><strong>Setting: </strong>The study was conducted at a tertiary medical center from January to July 2021.</p><p><strong>Methods: </strong>Surgeons assessed adhesions at four anatomical sites, scoring them from 0 (none) to 2 (dense), with a total possible score of 0-8. Severe adhesions were defined as a score of ≥5. Risk factors were analyzed using logistic regression to create a prediction model.</p><p><strong>Results: </strong>Overall, 341 women were included in the study. Significant predictors included the number of previous CS, maternal body mass index, maternal morbidity at the time of the previous CS, and operation time. The model predicted severe adhesions with 79.1% accuracy, a positive predictive value of 68.4%, and a negative predictive value of 79.5%.</p><p><strong>Limitations: </strong>Few risk factors, such as surgical history beyond cesarean sections, endometriosis, and pelvic inflammatory disease were not available. Additionally, the sample size of 341 women, while substantial, may limit the identification of further risk factors and the precision of the predictive model.</p><p><strong>Conclusion: </strong>The severity of most cases of post-CS adhesions can be predicted by a model which considers common risk factors.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"1-8"},"PeriodicalIF":2.0,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global, Regional, and National Prevalence and Disability-Adjusted Life-Years for Female Infertility: Results from a Global Burden of Disease Study, 1990-2019. 全球、地区和国家女性不孕症患病率和残疾调整寿命年数:1990-2019年全球疾病负担研究结果。
IF 2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-21 DOI: 10.1159/000542408
DongYi Shen, Sen Yang, Cong Qi, Hong Yang

Objectives: We aimed to determine the prevalence of female infertility in 204 countries and territories from 1990 to 2019.

Design: We evaluated the female infertility global burden between 1990 and 2019 in this systematic study.

Materials: The Global Health Data Exchange query tool (http://ghdx.healthdata.org/gbd-results-tool) and sociodemographic index (SDI) (http://ghdx.healthdata.org/data-type/estimate) provided data on the annual prevalence numbers, age-standardized prevalence rates (ASR), and disability-adjusted life-years (DALYs) of female infertility in 204 countries and territories from 1990 to 2019 for various age groups.

Setting: Female infertility has a devastating impact on the physical and mental health of individuals and national fertility. However, most of the previous studies on this subject were conducted on rather small sample sizes and have certain limitations.

Methods: We examined female infertility in terms of prevalence, ASR, and DALYs across different age groups in 204 countries and territories from 1990 to 2019 using data from the Global Health Data Exchange query tool.

Results: From 1990 to 2019, ASR and DALYs for female infertility increased globally. At the SDI quintile level, middle-SDI and high-middle-SDI countries exhibited a faster increase in the ASR of female infertility. In 2019, with the highest female infertility rate recorded among those between the ages of 30-34 years and the lowest among those between the ages of 45-49 years. In 2019, high-income North America recorded the highest proportion of primary infertility, while East Asia recorded the lowest proportion.

Limitations: First, the global burden of disease (GBD) database lacks data for some countries and regions. Second, data access and quality differ across locations. Third, the causes of infertility are not comprehensive, and data on Klinefelter in GBD 2019 in relation to primary infertility were absent.

Conclusion: Globally, the prevalence of DALYs and age-standardized female infertility rates increased from 1990 to 2019.

引言女性不孕症对个人的身心健康和国家的生育能力都会造成毁灭性的影响。然而,以往关于这一主题的大多数研究都是在样本量相当小的情况下进行的,具有一定的局限性。因此,我们旨在确定 1990 年至 2019 年期间 204 个国家和地区的女性不孕症发病率:我们利用全球健康数据交换查询工具提供的数据,研究了 1990 年至 2019 年期间 204 个国家和地区不同年龄组女性不孕症的患病率、年龄标准化患病率(ASR)和残疾调整生命年(DALYs):从 1990 年到 2019 年,全球女性不孕症的 ASR 和 DALYs 均有所增加。在社会人口指数(SDI)五分位水平上,中SDI和中高SDI国家的女性不孕症ASR增长较快。2019年,30-34岁年龄段的女性不孕率最高,45-49岁年龄段的女性不孕率最低。2019年,高收入的北美地区原发性不孕症比例最高,而东亚地区比例最低:首先,GBD数据库缺少一些国家和地区的数据。第二,各地数据的获取途径和质量不同。第三,不孕症病因不全面,GBD2019 中与原发性不孕症相关的 Klinefelter 数据为 0:从 1990 年到 2019 年,全球残疾调整寿命年数和年龄标准化女性不孕症患病率均有所上升。
{"title":"Global, Regional, and National Prevalence and Disability-Adjusted Life-Years for Female Infertility: Results from a Global Burden of Disease Study, 1990-2019.","authors":"DongYi Shen, Sen Yang, Cong Qi, Hong Yang","doi":"10.1159/000542408","DOIUrl":"10.1159/000542408","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to determine the prevalence of female infertility in 204 countries and territories from 1990 to 2019.</p><p><strong>Design: </strong>We evaluated the female infertility global burden between 1990 and 2019 in this systematic study.</p><p><strong>Materials: </strong>The Global Health Data Exchange query tool (<ext-link ext-link-type=\"uri\" xlink:href=\"http://ghdx.healthdata.org/gbd-results-tool\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">http://ghdx.healthdata.org/gbd-results-tool</ext-link>) and sociodemographic index (SDI) (<ext-link ext-link-type=\"uri\" xlink:href=\"http://ghdx.healthdata.org/data-type/estimate\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">http://ghdx.healthdata.org/data-type/estimate</ext-link>) provided data on the annual prevalence numbers, age-standardized prevalence rates (ASR), and disability-adjusted life-years (DALYs) of female infertility in 204 countries and territories from 1990 to 2019 for various age groups.</p><p><strong>Setting: </strong>Female infertility has a devastating impact on the physical and mental health of individuals and national fertility. However, most of the previous studies on this subject were conducted on rather small sample sizes and have certain limitations.</p><p><strong>Methods: </strong>We examined female infertility in terms of prevalence, ASR, and DALYs across different age groups in 204 countries and territories from 1990 to 2019 using data from the Global Health Data Exchange query tool.</p><p><strong>Results: </strong>From 1990 to 2019, ASR and DALYs for female infertility increased globally. At the SDI quintile level, middle-SDI and high-middle-SDI countries exhibited a faster increase in the ASR of female infertility. In 2019, with the highest female infertility rate recorded among those between the ages of 30-34 years and the lowest among those between the ages of 45-49 years. In 2019, high-income North America recorded the highest proportion of primary infertility, while East Asia recorded the lowest proportion.</p><p><strong>Limitations: </strong>First, the global burden of disease (GBD) database lacks data for some countries and regions. Second, data access and quality differ across locations. Third, the causes of infertility are not comprehensive, and data on Klinefelter in GBD 2019 in relation to primary infertility were absent.</p><p><strong>Conclusion: </strong>Globally, the prevalence of DALYs and age-standardized female infertility rates increased from 1990 to 2019.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"1-17"},"PeriodicalIF":2.0,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relation of Endocan Serum Levels with Patient Characteristics and Morphological Features of Uterine Fibroids: A Case-Control Study. Endocan(ESM-1)血清水平与子宫肌瘤患者特征和形态学特征的关系:病例对照研究。
IF 2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-19 DOI: 10.1159/000542405
Inci Başkır, Şebnem Özyer

Objectives: This study aimed to compare the serum endocan levels of patients with uterine fibroids and the healthy control group.

Design: A case-control study was designed. Participants/Materials: The study group includes women diagnosed with uterine fibroids, and the control group includes healthy women.

Setting: The study was conducted at a tertiary education and research hospital with 130 women (uterine fibroid group, n = 65; control group, n = 65).

Methods: Serum endocan levels were determined in the study and control groups using the ELISA method. The number of uterine fibroids was identified, and the volume of uterine fibroids was calculated with ellipsoid formula by ultrasonography. The primary outcome parameter was serum endocan levels in patients with uterine fibroids and healthy control groups. Second, it is aimed to determine the distribution of the serum endocan level of patients according to uterine fibroid number, volume, and clinical presentation.

Results: The mean serum endocan level of patient with uterine fibroid was 145.18 ± 169.86 (median: 94.10; Q25-Q75%: 54.50-116.50) pg/mL; it was 88.94 ± 54.21 (median: 76.9; Q25-Q75%: 64.20-152.65) pg/mL in the control group (p = 0.016). According to ROC analysis, cutoff value of the endocan level for uterine fibroid was determined as ≥133.1 pg/mL. For the cutoff value of 133.1 pg/mL, sensitivity was 36.92%, specificity was 89.23%, positive predictive value was 77.40%, and negative predictive value was 58.60%. Above this cutoff value, a 4.8-fold increased significant risk (OR) for uterine fibroid was detected.

Limitations: The major limitation of the study is the lack of histopathological examination.

Conclusion: Serum endocan levels were found to be higher in women with uterine fibroids compared to the control group, so endocan may be considered as a significant serum marker.

研究目的本研究旨在比较子宫肌瘤患者和健康对照组的血清内皮素水平:设计:病例对照研究。参与者/材料:研究组包括确诊为子宫肌瘤的妇女,对照组包括健康妇女:研究在一家三级教育研究医院进行,共有 130 名妇女参加(子宫肌瘤组 65 人,对照组 65 人):方法:采用 ELISA 方法测定研究组和对照组的血清内皮素水平。方法:采用 ELISA 方法测定研究组和对照组的血清内皮素水平,通过超声波检查确定子宫肌瘤的数量,并用椭圆公式计算子宫肌瘤的体积。主要结果参数是子宫肌瘤患者和健康对照组的血清内切酶水平。其次,根据子宫肌瘤数量、体积和临床表现确定患者血清内皮素水平的分布:结果:子宫肌瘤患者的平均血清内切酶水平为 145.18 ± 169.86(中位:94.10,Q25-Q75%:54.50-116.50) pg/mL,对照组为 88.94 ± 54.21(中位:76.9,Q25-Q75%:64.20-152.65) pg/mL(P=0.016)。根据 Roc 分析,确定子宫肌瘤的内切酶水平临界值为≥ 133.1 pg/mL。对于 133.1 pg/mL 的临界值,敏感性为 36.92%,特异性为 89.23%,阳性预测值为 77.40%,阴性预测值为 58.60%。超过该临界值,子宫肌瘤的显著风险(OR)增加了 4.8 倍:研究的主要局限性在于缺乏组织病理学检查:结论:与对照组相比,患有子宫肌瘤的妇女血清内皮素水平较高,因此内皮素可被视为一种重要的血清标志物。
{"title":"Relation of Endocan Serum Levels with Patient Characteristics and Morphological Features of Uterine Fibroids: A Case-Control Study.","authors":"Inci Başkır, Şebnem Özyer","doi":"10.1159/000542405","DOIUrl":"10.1159/000542405","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to compare the serum endocan levels of patients with uterine fibroids and the healthy control group.</p><p><strong>Design: </strong>A case-control study was designed. Participants/Materials: The study group includes women diagnosed with uterine fibroids, and the control group includes healthy women.</p><p><strong>Setting: </strong>The study was conducted at a tertiary education and research hospital with 130 women (uterine fibroid group, n = 65; control group, n = 65).</p><p><strong>Methods: </strong>Serum endocan levels were determined in the study and control groups using the ELISA method. The number of uterine fibroids was identified, and the volume of uterine fibroids was calculated with ellipsoid formula by ultrasonography. The primary outcome parameter was serum endocan levels in patients with uterine fibroids and healthy control groups. Second, it is aimed to determine the distribution of the serum endocan level of patients according to uterine fibroid number, volume, and clinical presentation.</p><p><strong>Results: </strong>The mean serum endocan level of patient with uterine fibroid was 145.18 ± 169.86 (median: 94.10; Q25-Q75%: 54.50-116.50) pg/mL; it was 88.94 ± 54.21 (median: 76.9; Q25-Q75%: 64.20-152.65) pg/mL in the control group (p = 0.016). According to ROC analysis, cutoff value of the endocan level for uterine fibroid was determined as ≥133.1 pg/mL. For the cutoff value of 133.1 pg/mL, sensitivity was 36.92%, specificity was 89.23%, positive predictive value was 77.40%, and negative predictive value was 58.60%. Above this cutoff value, a 4.8-fold increased significant risk (OR) for uterine fibroid was detected.</p><p><strong>Limitations: </strong>The major limitation of the study is the lack of histopathological examination.</p><p><strong>Conclusion: </strong>Serum endocan levels were found to be higher in women with uterine fibroids compared to the control group, so endocan may be considered as a significant serum marker.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"1-9"},"PeriodicalIF":2.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS). 基于法国全国报销数据库(SNDS)的数据,对辅助生殖技术中用于刺激卵巢的促性腺激素进行成本效益分析。
IF 2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-19 DOI: 10.1159/000542074
Isabelle Borget, Mehdi Benchaib, Philippine Poignant, Laetitia Rey, Gerard Harty, Vivek Chaudhari, Thomas D'hooghe, Juan-Enrique Schwarze, Isabelle Cedrin Durnerin, Claudia Roeder, Michael Grynberg
<p><strong>Objective: </strong>Various gonadotropins are used for ovarian stimulation (OS). This study investigated the cost-effectiveness of different gonadotropins based on real-world data from the French National Health Database (SNDS) over a 7-year follow-up of assisted reproductive technology (ART) treatments.</p><p><strong>Design: </strong>Cost-effectiveness analysis of different gonadotropins based on real-world data from the SNDS was conducted.</p><p><strong>Participants: </strong>Women from SNDS undergoing OS leading to oocyte pick-up registered between January 31, 2013, and December 31, 2018 (N = 245,534 stimulations), and receiving either recombinant human follicle stimulating hormone (r-hFSH alfa originator; 110,439), its biosimilars (12,287), or urinaries (mainly highly purified human menopausal gonadotropin [HP-hMG; 65,654] and marginally highly purified urinary-human follicle stimulating hormone [7,821]) were included (follow-up: December 31, 2019).</p><p><strong>Settings and methods: </strong>Clinical inputs for this model, including live birth (LB) and cumulative LB (CLB) were calculated from data as published in [Best Pract Res Clin Obstet Gynaecol. 2023;88:102308]. A decision-tree model was developed comprising pregnancy and live birth rate (LBR) states for a complete ART cycle, including one fresh and ≤4 frozen/thawed embryo transfers and related costs. Cost inputs included those of drugs, ART procedure, pregnancy and delivery, and adverse events. Cost per LB and CLB and incremental cost-effectiveness ratio (ICER) were assessed. Robustness of results was determined by comprehensive sensitivity analyses.</p><p><strong>Results: </strong>Overall, r-hFSH alfa originator was found to be associated with a lower cost per LB and per CLB (cost per LB: EUR 26,010; CLB: EUR 22,278) versus its biosimilars (cost per LB: EUR 28,037; CLB: EUR 23,807) and versus urinaries (cost per LB: EUR 26,636; CLB: EUR 23,335). Calculated ICERs with r-hFSH alfa for LB were EUR 5,538 and EUR 14,090, whereas for CLB were EUR 1,945 and EUR 13,742 versus biosimilars and urinaries, respectively. Cost-effectiveness acceptability curve showed that in a majority of iterations, r-hFSH alfa originator had a probability of being cost-effective at a hypothetical threshold of EUR 20,000/LB. Sensitivity analyses showed that the most important variable impacting the outcome in fresh transfers was the probability of birth for biosimilars and the probability of pregnancy for urinaries, while for cumulative transfers, it was the probability of pregnancy for biosimilars and the probability of birth for urinaries.</p><p><strong>Limitations: </strong>As the clinical data were obtained from a non-interventional study and not a randomized controlled trial, the results may still be susceptible to residual confounding or other biases.</p><p><strong>Conclusions: </strong>r-hFSH alfa originator is cost-effective compared to its biosimilars and to urinaries (mainly HP-hMG) and is as
目的:各种促性腺激素被用于卵巢刺激(OS)。本研究根据法国国家健康数据库(SNDS)的实际数据,对辅助生殖技术(ART)治疗的7年随访情况,对不同促性腺激素的成本效益进行了调查:设计:根据法国国家健康数据库(SNDS)的实际数据,对不同促性腺激素进行成本效益分析:纳入2013年1月31日至2018年12月31日期间(N=245,534次促排卵)登记的、接受r-hFSH alfa原体(110,439次)、其生物仿制药(12,287次)或尿液(主要为HP-hMG[65,654次],少量为u-hFSH-HP[7,821次])的接受OS导致卵母细胞拾取的SNDS妇女(随访时间:2019年12月31日):该模型的临床输入数据,包括活产(LB)和累积活产(CLB),均根据 Grynberg 等人在 2022 年发表的数据计算得出。建立的决策树模型包括一个完整 ART 周期(包括一次新鲜胚胎移植和≤4 次冷冻/解冻胚胎移植)的妊娠和活产率 (LBR) 状态以及相关成本。成本投入包括药物、ART 过程、妊娠和分娩以及不良事件的成本投入。评估了每 LB 和 CLB 的成本以及增量成本效益比 (ICER)。通过综合敏感性分析确定了结果的稳健性:总体而言,r-hFSH alfa原研药与生物仿制药(每LB成本:26,010欧元;每CLB成本:22,278欧元)和尿液(每LB成本:26,636欧元;每CLB成本:23,335欧元)相比,每LB和每CLB成本更低(每LB成本:26,010欧元;每CLB成本:22,278欧元)。与生物仿制药和尿液相比,r-hFSH alfa治疗LB的ICER计算值分别为5538欧元和14090欧元,而治疗CLB的ICER计算值分别为1945欧元和13742欧元。成本效益可接受性曲线显示,在大多数迭代中,r-hFSH alfa 原研药在假设阈值为 20,000 欧元/活产时具有成本效益。敏感性分析表明,在新鲜转移中,影响结果的最重要变量是生物仿制药的出生概率和尿液的怀孕概率,而在累积转移中,影响结果的最重要变量是生物仿制药的怀孕概率和尿液的出生概率:结论:与生物仿制药和尿液(主要是 HP-hMG)相比,r-hFSH alfa 原研药具有成本效益,与这些促性腺激素相比,其每 LB 成本较低,主要原因是其活产有效率较高。
{"title":"A Cost-Effectiveness Analysis of Gonadotropins Used for Ovarian Stimulation during Assisted Reproductive Technology Based on Data from the French Nationwide Claims Database (SNDS).","authors":"Isabelle Borget, Mehdi Benchaib, Philippine Poignant, Laetitia Rey, Gerard Harty, Vivek Chaudhari, Thomas D'hooghe, Juan-Enrique Schwarze, Isabelle Cedrin Durnerin, Claudia Roeder, Michael Grynberg","doi":"10.1159/000542074","DOIUrl":"10.1159/000542074","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Various gonadotropins are used for ovarian stimulation (OS). This study investigated the cost-effectiveness of different gonadotropins based on real-world data from the French National Health Database (SNDS) over a 7-year follow-up of assisted reproductive technology (ART) treatments.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;Cost-effectiveness analysis of different gonadotropins based on real-world data from the SNDS was conducted.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Participants: &lt;/strong&gt;Women from SNDS undergoing OS leading to oocyte pick-up registered between January 31, 2013, and December 31, 2018 (N = 245,534 stimulations), and receiving either recombinant human follicle stimulating hormone (r-hFSH alfa originator; 110,439), its biosimilars (12,287), or urinaries (mainly highly purified human menopausal gonadotropin [HP-hMG; 65,654] and marginally highly purified urinary-human follicle stimulating hormone [7,821]) were included (follow-up: December 31, 2019).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Settings and methods: &lt;/strong&gt;Clinical inputs for this model, including live birth (LB) and cumulative LB (CLB) were calculated from data as published in [Best Pract Res Clin Obstet Gynaecol. 2023;88:102308]. A decision-tree model was developed comprising pregnancy and live birth rate (LBR) states for a complete ART cycle, including one fresh and ≤4 frozen/thawed embryo transfers and related costs. Cost inputs included those of drugs, ART procedure, pregnancy and delivery, and adverse events. Cost per LB and CLB and incremental cost-effectiveness ratio (ICER) were assessed. Robustness of results was determined by comprehensive sensitivity analyses.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Overall, r-hFSH alfa originator was found to be associated with a lower cost per LB and per CLB (cost per LB: EUR 26,010; CLB: EUR 22,278) versus its biosimilars (cost per LB: EUR 28,037; CLB: EUR 23,807) and versus urinaries (cost per LB: EUR 26,636; CLB: EUR 23,335). Calculated ICERs with r-hFSH alfa for LB were EUR 5,538 and EUR 14,090, whereas for CLB were EUR 1,945 and EUR 13,742 versus biosimilars and urinaries, respectively. Cost-effectiveness acceptability curve showed that in a majority of iterations, r-hFSH alfa originator had a probability of being cost-effective at a hypothetical threshold of EUR 20,000/LB. Sensitivity analyses showed that the most important variable impacting the outcome in fresh transfers was the probability of birth for biosimilars and the probability of pregnancy for urinaries, while for cumulative transfers, it was the probability of pregnancy for biosimilars and the probability of birth for urinaries.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Limitations: &lt;/strong&gt;As the clinical data were obtained from a non-interventional study and not a randomized controlled trial, the results may still be susceptible to residual confounding or other biases.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;r-hFSH alfa originator is cost-effective compared to its biosimilars and to urinaries (mainly HP-hMG) and is as","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"1-15"},"PeriodicalIF":2.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of Coping with Primary Dysmenorrhea in Women according to Their Level of Physical Activity: A Cross-Sectional Observational Study. 根据妇女的体育活动水平分析她们如何应对原发性痛经:一项横断面观察研究。
IF 2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-19 DOI: 10.1159/000542096
Alfonso Javier Ibáñez-Vera, María Cobertera-Pintor, Lorena Del Carmen Tejero-Olalla, Esther Díaz-Mohedo

Introduction: Primary dysmenorrhea (PD) is one of the most common gynecological pathologies in women. The aim was to determine the differences in coping with PD in women who practice high-intensity sport, compared to women who are less physically active.

Methods: This was a cross-sectional observational study. A total of 476 women were recruited and administered a Google Form multiple-choice questionnaire divided into six sections. The following scales were used: Numerical Pain Rating Scale (NPRS), Pain Catastrophizing Scale (PCS), Menstruation-related Quality of Life Questionnaire (MQOL-22), Tampa Scale for Kinesiophobia (TSK), and Borg scale.

Results: The 389 participants meeting the inclusion criteria were divided into three groups according to their score in Borg test: high-intensity physical activity group (n = 178), moderate-intensity physical activity group (n = 101), and low-intensity physical activity group (n = 110) for those scoring under 4. ANOVA analysis showed statistical significance only for PCS (p = 0.024). Tukey group per group comparison determined differences between high-intensity physical activity group and low-intensity physical activity group regarding PCS (p = 0.018). Spearman correlation analysis showed a high relation between PCS and NPRS (r = 0.664) and between MQOL-22 and NPRS (r = -0.562).

Conclusion: The intensity of the exercise training does not influence PD-related pain perception nor kinesiophobia. High-intensity exercise reduces catastrophizing when compared with sedentary or low-intensity exercise. Level of catastrophizing is highly related with perceived pain and quality of life in menstruation in these PD patients.

目的:原发性痛经(PD)是女性最常见的妇科疾病之一。本研究旨在确定与运动量较少的女性相比,从事高强度运动的女性在应对原发性痛经方面是否存在差异:设计:这是一项横断面观察研究:共招募了 476 名女性,并对其进行了 Google Form 多项选择问卷调查,问卷分为六个部分。使用的量表如下数字疼痛评定量表(NPRS)、疼痛灾难化量表(PCS)、月经相关生活质量问卷(MQOL-22)、坦帕运动恐惧症量表(TSK)和博格量表。结果 符合纳入标准的 389 名参与者根据博格测试得分分为三组:高强度体育锻炼组(178 人)、中等强度体育锻炼组(101 人)和低强度体育锻炼组(110 人)(得分低于 4 分)。方差分析显示,只有 PCS 具有统计学意义(p= 0.024)。Tukey 组间比较确定了高强度体育锻炼组和低强度体育锻炼组在 PCS 方面的差异(p=0.018)。斯皮尔曼相关性分析表明,PCS 与 NPRS(r= 0.664)以及 MQOL-22 与 NPRS(r= -0.562)之间存在高度相关性。局限性 本研究没有为所有参与者提供统一的锻炼方案,因此每位参与者的体育锻炼水平在时间、强度和频率方面都不尽相同,这在分析结果时可能至关重要 结论 根据我们的数据,锻炼训练的强度不会影响与帕金森病相关的疼痛感或运动恐惧。与久坐不动或低强度运动相比,高强度运动可减少灾难感。这些帕金森病患者的灾难化程度与月经期的疼痛感和生活质量高度相关。综上所述,建议进行高强度体育锻炼,以减轻原发性痛经妇女的灾难化程度。
{"title":"Characterization of Coping with Primary Dysmenorrhea in Women according to Their Level of Physical Activity: A Cross-Sectional Observational Study.","authors":"Alfonso Javier Ibáñez-Vera, María Cobertera-Pintor, Lorena Del Carmen Tejero-Olalla, Esther Díaz-Mohedo","doi":"10.1159/000542096","DOIUrl":"10.1159/000542096","url":null,"abstract":"<p><strong>Introduction: </strong>Primary dysmenorrhea (PD) is one of the most common gynecological pathologies in women. The aim was to determine the differences in coping with PD in women who practice high-intensity sport, compared to women who are less physically active.</p><p><strong>Methods: </strong>This was a cross-sectional observational study. A total of 476 women were recruited and administered a Google Form multiple-choice questionnaire divided into six sections. The following scales were used: Numerical Pain Rating Scale (NPRS), Pain Catastrophizing Scale (PCS), Menstruation-related Quality of Life Questionnaire (MQOL-22), Tampa Scale for Kinesiophobia (TSK), and Borg scale.</p><p><strong>Results: </strong>The 389 participants meeting the inclusion criteria were divided into three groups according to their score in Borg test: high-intensity physical activity group (n = 178), moderate-intensity physical activity group (n = 101), and low-intensity physical activity group (n = 110) for those scoring under 4. ANOVA analysis showed statistical significance only for PCS (p = 0.024). Tukey group per group comparison determined differences between high-intensity physical activity group and low-intensity physical activity group regarding PCS (p = 0.018). Spearman correlation analysis showed a high relation between PCS and NPRS (r = 0.664) and between MQOL-22 and NPRS (r = -0.562).</p><p><strong>Conclusion: </strong>The intensity of the exercise training does not influence PD-related pain perception nor kinesiophobia. High-intensity exercise reduces catastrophizing when compared with sedentary or low-intensity exercise. Level of catastrophizing is highly related with perceived pain and quality of life in menstruation in these PD patients.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"1-11"},"PeriodicalIF":2.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Malignant Transformation of Squamous Cell Carcinoma in Mature Cystic Teratoma of the Ovary: A Systematic Review and Meta-Analysis of Data. 卵巢成熟囊性畸胎瘤中鳞状细胞癌的恶性转化--数据的系统回顾和元分析。
IF 2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-19 DOI: 10.1159/000542672
Sarah Y Wu, Andrea Giannini, Marlene Girardo, Alessandra Schmitt, Javier F Magrina, Kristina Butler

Introduction: Mature cystic teratomas (MCTs) are the most common neoplasm of the ovary, occurring in 10-20% of women during their lifetimes. MCTs may rarely undergo malignant transformation, of which squamous cell carcinoma is the most common histopathology. This rare malignancy is poorly understood; therefore, medical and surgical treatment have yet to be optimized to produce the best outcomes for patients diagnosed with squamous cell carcinoma in MCT (SCC-MCT). We aimed to characterize the clinicopathologic features, surgical treatment, adjuvant treatment, and prognosis of SCC-MCT.

Methods: A systematic literature search was performed using MEDLINE through Ovid and PubMed for relevant articles on malignant transformation of squamous cell carcinoma in MCT of the ovary. 155 studies were identified, yielding clinical information on 654 unique patients. Univariate and multivariate analyses were performed to assess factors influencing overall survival (OS). Disease-free survival and OS of cases with follow-up were assessed by the Kaplan-Meier life table analysis. Survival rates were assessed with the log-rank test.

Results: We found that SCC-MCT generally presented in postmenopausal patients with tumor sizes greater than 10 cm. Patients diagnosed with FIGO stage I disease had better survival than later stage disease, and higher FIGO stage was independently associated with worse OS. Longer OS was associated with younger age at diagnosis, low preoperative levels of SCC Ag and CA-125, and treatment with lymphadenectomy. Chemotherapy or radiotherapy were not associated with improved survival.

Conclusion: The prognosis of SCC-MCT is dependent on a variety of factors including age, serum tumor marker levels, and surgical treatment. Prognosis regardless of adjuvant treatment modality chosen for late-stage malignancy is generally poor. Future research focusing on collecting patient outcome data from international centers is needed to better guide treatment choices.

背景:成熟囊性畸胎瘤(MCT)是卵巢最常见的肿瘤,10%-20%的女性一生中都会患上这种肿瘤。成熟囊性畸胎瘤很少会发生恶变,其中鳞状细胞癌是最常见的组织病理学类型。人们对这种罕见的恶性肿瘤知之甚少,因此,对于确诊为 MCT 鳞状细胞癌(SCC-MCT)的患者,医疗和手术治疗仍有待优化,以获得最佳疗效:研究设计:研究设计:通过 Ovid 和 Pubmed,使用 MEDLINE 对卵巢成熟囊性畸胎瘤鳞状细胞癌恶变的相关文章进行了系统性文献检索。共确定了 155 项研究,获得了 654 名患者的临床信息。研究人员进行了单变量和多变量分析,以评估影响总生存率的因素。随访病例的无病生存率和总生存率通过卡普兰-梅耶生命表分析法进行评估。生存率用对数秩检验进行评估:我们发现,SCC-MCT通常发生在绝经后患者中,肿瘤大小超过10厘米。确诊为 FIGO 分期 I 期的患者比晚期患者的生存率更高,FIGO 分期越高,总生存率越低。总生存期较长与诊断时年龄较小、术前 SCC Ag 和 CA-125 水平较低以及接受淋巴结切除治疗有关。化疗或放疗与生存率的提高无关:结论:SCC-MCT的预后取决于多种因素,包括年龄、血清肿瘤标志物水平和手术治疗。晚期恶性肿瘤无论选择哪种辅助治疗方式,预后都普遍较差。未来的研究需要重点收集国际中心的患者预后数据,以便更好地指导治疗选择。
{"title":"Malignant Transformation of Squamous Cell Carcinoma in Mature Cystic Teratoma of the Ovary: A Systematic Review and Meta-Analysis of Data.","authors":"Sarah Y Wu, Andrea Giannini, Marlene Girardo, Alessandra Schmitt, Javier F Magrina, Kristina Butler","doi":"10.1159/000542672","DOIUrl":"10.1159/000542672","url":null,"abstract":"<p><strong>Introduction: </strong>Mature cystic teratomas (MCTs) are the most common neoplasm of the ovary, occurring in 10-20% of women during their lifetimes. MCTs may rarely undergo malignant transformation, of which squamous cell carcinoma is the most common histopathology. This rare malignancy is poorly understood; therefore, medical and surgical treatment have yet to be optimized to produce the best outcomes for patients diagnosed with squamous cell carcinoma in MCT (SCC-MCT). We aimed to characterize the clinicopathologic features, surgical treatment, adjuvant treatment, and prognosis of SCC-MCT.</p><p><strong>Methods: </strong>A systematic literature search was performed using MEDLINE through Ovid and PubMed for relevant articles on malignant transformation of squamous cell carcinoma in MCT of the ovary. 155 studies were identified, yielding clinical information on 654 unique patients. Univariate and multivariate analyses were performed to assess factors influencing overall survival (OS). Disease-free survival and OS of cases with follow-up were assessed by the Kaplan-Meier life table analysis. Survival rates were assessed with the log-rank test.</p><p><strong>Results: </strong>We found that SCC-MCT generally presented in postmenopausal patients with tumor sizes greater than 10 cm. Patients diagnosed with FIGO stage I disease had better survival than later stage disease, and higher FIGO stage was independently associated with worse OS. Longer OS was associated with younger age at diagnosis, low preoperative levels of SCC Ag and CA-125, and treatment with lymphadenectomy. Chemotherapy or radiotherapy were not associated with improved survival.</p><p><strong>Conclusion: </strong>The prognosis of SCC-MCT is dependent on a variety of factors including age, serum tumor marker levels, and surgical treatment. Prognosis regardless of adjuvant treatment modality chosen for late-stage malignancy is generally poor. Future research focusing on collecting patient outcome data from international centers is needed to better guide treatment choices.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"1-13"},"PeriodicalIF":2.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ultrasound Diagnosis of Bowel Endometriosis. 肠道子宫内膜异位症的超声诊断。
IF 2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-15 DOI: 10.1159/000542563
Simone Ferrero, Fabio Barra, Umberto Perrone, Michele Paudice, Valerio Gaetano Vellone

Background: Bowel endometriosis is one of the more severe manifestations of deep endometriosis; it may cause pain and intestinal symptoms. The noninvasive diagnosis of bowel endometriosis is of crucial importance in planning the management of patients affected by this condition.

Objectives: This review aims to describe how transvaginal ultrasonography (TVS) is performed in patients with suspicion of rectosigmoid endometriosis, the diagnostic performance, and the strengths and limitations of this technique.

Methods: To identify relevant literature, a literature search was performed across the PubMed and Google Scholar databases up to July 2024.

Outcome: Numerous meta-analyses have demonstrated that TVS has high diagnostic accuracy in diagnosing rectosigmoid endometriosis. Rectosigmoid nodules can present with different morphological characteristics, but they are typically described as irregular, hypoechoic nodules located in the anterior wall of the rectosigmoid colon. The presence of "soft markers," such as a negative sliding sign and kissing ovaries, can further reinforce the diagnosis of this condition. Posterolateral parametrial involvement often coexists with large rectal nodules. Introducing water contrast into the rectosigmoid does not improve the performance of TVS in diagnosing rectosigmoid endometriosis.

Conclusions and outlook: TVS should be the first-line investigation in women suspected of having rectosigmoid endometriosis. The widespread use of TVS for the diagnosis of intestinal endometriosis can reduce diagnostic delays and facilitate the treatment of patients affected by this condition.

背景 肠道子宫内膜异位症是深部子宫内膜异位症中较为严重的一种表现,可引起疼痛和肠道症状。肠道子宫内膜异位症的无创诊断对于计划治疗受此疾病影响的患者至关重要。目的 本综述旨在描述经阴道超声检查(TVS)在怀疑直肠乙状结肠子宫内膜异位症患者中的应用方式、诊断效果以及该技术的优势和局限性。方法 为了确定相关文献,我们在 PubMed 和 Google Scholar 数据库中进行了文献检索,检索时间截至 2024 年 7 月。结果 大量荟萃分析表明,TVS 在诊断直肠乙状结肠子宫内膜异位症方面具有很高的诊断准确性。直肠乙状结肠结节可表现出不同的形态特征,但通常被描述为位于直肠乙状结肠前壁的不规则、低回声结节。阴性滑动征和亲吻卵巢等 "软标志物 "的出现可进一步强化该病症的诊断。宫旁后外侧受累常与直肠大结节同时存在。将水造影剂引入直肠乙状结肠并不能提高 TVS 诊断直肠乙状结肠子宫内膜异位症的效果。结论与展望 TVS 应作为疑似直肠乙状结肠子宫内膜异位症妇女的一线检查方法。广泛使用 TVS 诊断肠道子宫内膜异位症可减少诊断延误,促进对该病患者的治疗。
{"title":"Ultrasound Diagnosis of Bowel Endometriosis.","authors":"Simone Ferrero, Fabio Barra, Umberto Perrone, Michele Paudice, Valerio Gaetano Vellone","doi":"10.1159/000542563","DOIUrl":"10.1159/000542563","url":null,"abstract":"<p><strong>Background: </strong>Bowel endometriosis is one of the more severe manifestations of deep endometriosis; it may cause pain and intestinal symptoms. The noninvasive diagnosis of bowel endometriosis is of crucial importance in planning the management of patients affected by this condition.</p><p><strong>Objectives: </strong>This review aims to describe how transvaginal ultrasonography (TVS) is performed in patients with suspicion of rectosigmoid endometriosis, the diagnostic performance, and the strengths and limitations of this technique.</p><p><strong>Methods: </strong>To identify relevant literature, a literature search was performed across the PubMed and Google Scholar databases up to July 2024.</p><p><strong>Outcome: </strong>Numerous meta-analyses have demonstrated that TVS has high diagnostic accuracy in diagnosing rectosigmoid endometriosis. Rectosigmoid nodules can present with different morphological characteristics, but they are typically described as irregular, hypoechoic nodules located in the anterior wall of the rectosigmoid colon. The presence of \"soft markers,\" such as a negative sliding sign and kissing ovaries, can further reinforce the diagnosis of this condition. Posterolateral parametrial involvement often coexists with large rectal nodules. Introducing water contrast into the rectosigmoid does not improve the performance of TVS in diagnosing rectosigmoid endometriosis.</p><p><strong>Conclusions and outlook: </strong>TVS should be the first-line investigation in women suspected of having rectosigmoid endometriosis. The widespread use of TVS for the diagnosis of intestinal endometriosis can reduce diagnostic delays and facilitate the treatment of patients affected by this condition.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"1-10"},"PeriodicalIF":2.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assisted Reproductive Technology, Pregnancy, and Recurrent Disease in Melanoma Patients: A 30-Year Single Institution Experience. 黑色素瘤患者的辅助生殖技术、妊娠和复发疾病:30 年的单一机构经验。
IF 2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-14 DOI: 10.1159/000541566
Sander Kelderman, Jorine de Haan, Dachmar Rhijnsburger, Abigael Bouwman, Christianne De Groot, John Haanen, John Coulter, Winan Van Houdt, Frédéric Amant, Christianne Lok
<p><strong>Objectives: </strong>The primary aim of this study was to assess differences in melanoma recurrence between patients conceiving spontaneously versus those undergoing assisted reproductive technology (ART) and to determine use of ART in post-melanoma patients. A secondary aim was to describe the use of immunotherapy as a novel treatment regimen for metastatic melanoma in a cohort of fertile patients.</p><p><strong>Design: </strong>This study is a 30-year analysis including data from a single-center questionnaire and a retrospective cohort study. Participants/Materials: Women of childbearing age with a history of melanoma were requested to participate in our study. We selected patients who underwent either primary melanoma treatment or treatment of local/distant recurrence at our institute between 1994 and 2021. Each participant received a questionnaire and informed consent form. The questions concerned general health, primary tumor characteristics, utilization of ART, subsequent pregnancies, and development of recurrent melanoma. Additional information was collected from the medical files.</p><p><strong>Setting: </strong>The research was conducted in a dedicated oncology center and tertiary referral center for melanoma in The Netherlands.</p><p><strong>Methods: </strong>Participants received the questionnaires by mail. Six weeks later a reminder was sent to nonresponders. Analysis was performed using descriptive statistics. For comparisons between groups, chi-square tests were used. p value was considered significant when below 0.05. A clinically relevant difference in recurrence rate was defined as a 10% difference.</p><p><strong>Results: </strong>A total of 498 questionnaires were available for analyses, 449 from living patients and 49 from relatives of diseased patients. One hundred and seventy-nine patients (36%) with a history of melanoma became pregnant following their diagnosis. There was no difference in the recurrence rate between patients who became pregnant after the diagnosis of melanoma and those who never subsequently conceived (37% vs. 35%, p = 0.609). In the total cohort, 28 patients (6%) attempted to conceive using ART, and eight of them experienced disease recurrence. A total of 58 patients (22% of patients since 2006) were treated with immunotherapy.</p><p><strong>Limitations: </strong>The main limitations of the study are its size, observational design, and questionnaire methodology.</p><p><strong>Conclusions: </strong>Pregnancy did not increase the risk of recurrent melanoma. The group of patients conceiving after ART was small, and therefore, it is difficult to confidently conclude that the recurrence risk is comparable to the other groups. Prospective international registration of these patients, their oncologic follow-up and possible use of assisted reproduction, will provide valuable information to determine any potential association between ART and risk of recurrent melanoma. This would enable health profession
研究目的 本研究旨在评估自然受孕患者与接受辅助生殖技术(ART)治疗的患者在黑色素瘤复发方面的差异,确定黑色素瘤术后患者对 ART 的使用情况,并研究对这一特殊患者群体进行咨询的影响。设计 本研究是一项为期 30 年的分析,包括来自单个中心问卷调查和回顾性队列研究的数据。参与者/材料 我们要求有黑色素瘤病史的育龄妇女参与研究。我们选择了 1994 年至 2021 年期间在本研究所接受原发性黑色素瘤治疗或局部/远处复发治疗的患者。每位参与者都收到了一份调查问卷和知情同意书。问题涉及一般健康状况、原发肿瘤特征、抗逆转录病毒疗法的使用情况、后续妊娠情况以及黑色素瘤复发情况。其他信息则从医疗档案中收集。研究地点 研究在荷兰一家专门的肿瘤中心和黑色素瘤三级转诊中心进行。方法 参与者通过邮件收到问卷。六周后向未回复者发送催复函。采用描述性统计方法进行分析。组间比较采用卡方检验。P 值低于 0.05 即为显著。复发率的临床相关性差异定义为 10%。结果 共有 498 份问卷可供分析,其中 449 份来自在世患者,49 份来自患者亲属。179名有黑色素瘤病史的患者(36%)在确诊后怀孕。在这组患者中,有 28 名患者(16%)试图通过抗逆转录病毒疗法受孕,其中 8 人疾病复发。确诊黑色素瘤后怀孕的患者与从未怀孕的患者的复发率没有差异(37% vs 35%,P=0.609)。局限性 该研究的主要局限性在于其规模、观察性设计和问卷调查方法。结论 怀孕不会增加黑色素瘤复发的风险。抗逆转录病毒疗法后怀孕的患者人数较少,因此很难有把握地断定复发风险与其他组别相当。对这些患者进行前瞻性的国际登记、肿瘤学随访以及可能使用的辅助生殖技术,将为确定抗逆转录病毒疗法与黑色素瘤复发风险之间的潜在联系提供宝贵的信息。这将有助于医疗专业人员制定监控策略,并为希望怀孕的患者提供孕前咨询。
{"title":"Assisted Reproductive Technology, Pregnancy, and Recurrent Disease in Melanoma Patients: A 30-Year Single Institution Experience.","authors":"Sander Kelderman, Jorine de Haan, Dachmar Rhijnsburger, Abigael Bouwman, Christianne De Groot, John Haanen, John Coulter, Winan Van Houdt, Frédéric Amant, Christianne Lok","doi":"10.1159/000541566","DOIUrl":"10.1159/000541566","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objectives: &lt;/strong&gt;The primary aim of this study was to assess differences in melanoma recurrence between patients conceiving spontaneously versus those undergoing assisted reproductive technology (ART) and to determine use of ART in post-melanoma patients. A secondary aim was to describe the use of immunotherapy as a novel treatment regimen for metastatic melanoma in a cohort of fertile patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design: &lt;/strong&gt;This study is a 30-year analysis including data from a single-center questionnaire and a retrospective cohort study. Participants/Materials: Women of childbearing age with a history of melanoma were requested to participate in our study. We selected patients who underwent either primary melanoma treatment or treatment of local/distant recurrence at our institute between 1994 and 2021. Each participant received a questionnaire and informed consent form. The questions concerned general health, primary tumor characteristics, utilization of ART, subsequent pregnancies, and development of recurrent melanoma. Additional information was collected from the medical files.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Setting: &lt;/strong&gt;The research was conducted in a dedicated oncology center and tertiary referral center for melanoma in The Netherlands.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Participants received the questionnaires by mail. Six weeks later a reminder was sent to nonresponders. Analysis was performed using descriptive statistics. For comparisons between groups, chi-square tests were used. p value was considered significant when below 0.05. A clinically relevant difference in recurrence rate was defined as a 10% difference.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 498 questionnaires were available for analyses, 449 from living patients and 49 from relatives of diseased patients. One hundred and seventy-nine patients (36%) with a history of melanoma became pregnant following their diagnosis. There was no difference in the recurrence rate between patients who became pregnant after the diagnosis of melanoma and those who never subsequently conceived (37% vs. 35%, p = 0.609). In the total cohort, 28 patients (6%) attempted to conceive using ART, and eight of them experienced disease recurrence. A total of 58 patients (22% of patients since 2006) were treated with immunotherapy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Limitations: &lt;/strong&gt;The main limitations of the study are its size, observational design, and questionnaire methodology.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Pregnancy did not increase the risk of recurrent melanoma. The group of patients conceiving after ART was small, and therefore, it is difficult to confidently conclude that the recurrence risk is comparable to the other groups. Prospective international registration of these patients, their oncologic follow-up and possible use of assisted reproduction, will provide valuable information to determine any potential association between ART and risk of recurrent melanoma. This would enable health profession","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"1-8"},"PeriodicalIF":2.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy or Tyrosine Kinase Inhibitors in Advanced Endometrial Cancer: A Systematic Review and Meta-Analysis. 免疫检查点抑制剂联合化疗或酪氨酸激酶抑制剂治疗晚期子宫内膜癌的疗效和安全性:系统综述与荟萃分析。
IF 2 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2024-11-04 DOI: 10.1159/000541617
Yuting Li, Shixiu Li, Juan Liang

Objective: The objective of this meta-analysis was to conduct a comprehensive assessment of the therapeutic effectiveness and safety profile of the combination of immune checkpoint inhibitors (ICIs) with either chemotherapy or tyrosine kinase inhibitors (TKIs) in the treatment of advanced-stage endometrial cancer (EC).

Methods: This meta-analysis conducted a thorough literature search across PubMed, Cochrane Library, Embase, and Web of Science databases from their earliest records up to November 18, 2023, identifying qualified randomized controlled trials (RCTs), cohort studies, and single-arm trials for inclusion in the analysis. The meta-analysis were performed to quantify and analyzed the evidence from the existing literature, focusing on outcomes including the objective response rate (ORR), disease control rate (DCR), duration of response, overall survival (OS), progression-free survival (PFS), and adverse events (AEs).

Results: A total of 13 studies were included. In terms of ICI combined with chemotherapy, the single-arm trials showed that ICI combined with chemotherapy was effective in improving the ORR, but the overall rate of AE was higher. The results based on RCT suggested that ICI combined with chemotherapy resulted in a longer PFS of 12-24 months and OS of 18 months compared to the control group in advanced EC. In terms of ICI combined with TKI, the pooled ORR was 39.0%, the pooled DCR was 79.9%, the pooled OS rate was 50.4%, and the pooled overall AE rate was 95.8%, the pooled grade ≥3 AE rate was 73.8%, the pooled median progression-free survival was 6.126 months, and pooled OS was 15.099 months in advanced EC.

Conclusions: The integrative therapeutic approach combining ICIs with chemotherapy or TKIs demonstrates notable clinical efficacy in advanced EC, which can prolong the survival and help disease control. Nevertheless, it is imperative for clinicians to be vigilant regarding the potential for adverse reactions to emerge. In addition, more RCTs are needed to solidify this study's efficacy and safety further.

研究目的本荟萃分析旨在全面评估免疫检查点抑制剂(ICIs)与化疗或酪氨酸激酶抑制剂(TKIs)联合治疗晚期子宫内膜癌(EC)的疗效和安全性:这项荟萃分析在PubMed、Cochrane图书馆、Embase和Web of Science数据库中进行了全面的文献检索,从最早的记录到2023年11月18日,确定了合格的随机对照试验(RCT)、队列研究和单臂试验纳入分析。荟萃分析对现有文献中的证据进行量化和分析,重点关注客观反应率(ORR)、疾病控制率(DCR)、反应持续时间(DOR)、总生存期(OS)、无进展生存期(PFS)和不良事件(AE)等结果:结果:共纳入 13 项研究。在 ICI 联合化疗方面,单臂试验显示 ICI 联合化疗能有效提高 ORR,但 AE 的总发生率较高。基于RCT的结果表明,与对照组相比,ICI联合化疗可使晚期EC的PFS延长12-24个月,OS延长18个月。ICI联合TKI治疗晚期EC的总ORR为39.0%,总DCR为79.9%,总OS为50.4%,总AE为95.8%,总≥3级AE为73.8%,总中位无进展生存期(mPFS)为6.126个月,总OS为15.099个月:结论:将 ICIs 与化疗或 TKIs 相结合的综合治疗方法在晚期 EC 中具有显著的临床疗效,可延长生存期并有助于疾病控制。然而,临床医生必须对可能出现的不良反应保持警惕。此外,还需要更多的研究试验来进一步巩固这项研究的疗效和安全性。
{"title":"Efficacy and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy or Tyrosine Kinase Inhibitors in Advanced Endometrial Cancer: A Systematic Review and Meta-Analysis.","authors":"Yuting Li, Shixiu Li, Juan Liang","doi":"10.1159/000541617","DOIUrl":"10.1159/000541617","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this meta-analysis was to conduct a comprehensive assessment of the therapeutic effectiveness and safety profile of the combination of immune checkpoint inhibitors (ICIs) with either chemotherapy or tyrosine kinase inhibitors (TKIs) in the treatment of advanced-stage endometrial cancer (EC).</p><p><strong>Methods: </strong>This meta-analysis conducted a thorough literature search across PubMed, Cochrane Library, Embase, and Web of Science databases from their earliest records up to November 18, 2023, identifying qualified randomized controlled trials (RCTs), cohort studies, and single-arm trials for inclusion in the analysis. The meta-analysis were performed to quantify and analyzed the evidence from the existing literature, focusing on outcomes including the objective response rate (ORR), disease control rate (DCR), duration of response, overall survival (OS), progression-free survival (PFS), and adverse events (AEs).</p><p><strong>Results: </strong>A total of 13 studies were included. In terms of ICI combined with chemotherapy, the single-arm trials showed that ICI combined with chemotherapy was effective in improving the ORR, but the overall rate of AE was higher. The results based on RCT suggested that ICI combined with chemotherapy resulted in a longer PFS of 12-24 months and OS of 18 months compared to the control group in advanced EC. In terms of ICI combined with TKI, the pooled ORR was 39.0%, the pooled DCR was 79.9%, the pooled OS rate was 50.4%, and the pooled overall AE rate was 95.8%, the pooled grade ≥3 AE rate was 73.8%, the pooled median progression-free survival was 6.126 months, and pooled OS was 15.099 months in advanced EC.</p><p><strong>Conclusions: </strong>The integrative therapeutic approach combining ICIs with chemotherapy or TKIs demonstrates notable clinical efficacy in advanced EC, which can prolong the survival and help disease control. Nevertheless, it is imperative for clinicians to be vigilant regarding the potential for adverse reactions to emerge. In addition, more RCTs are needed to solidify this study's efficacy and safety further.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"1-14"},"PeriodicalIF":2.0,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Gynecologic and Obstetric Investigation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1